Novo Nordisk will invest more than $6 billion to expand manufacturing facilities in Denmark, the company said Nov. 10. The facility will support increased production capacity for its GLP-1 drugs Ozempic and Wegovy, and other chronic disease treatments.
Read the full post on Becker's Hospital Review - Healthcare News
